Product image of Metoprolol Retard Teva (Metoprolol Succinate (Ph. Eur.)) supplied by GNH India

Metoprolol Retard Teva

Active Ingredient:
Metoprolol Succinate (Ph. Eur.)
Origin:
EU

Metoprolol Retard Teva (Metoprolol Succinate (Ph. Eur.))

Metoprolol succinate, the active ingredient in Metoprolol Retard, is a beta blocker presented as an extended‑release tablet for oral use. It reduces blood pressure, relieves angina, improves heart‑failure symptoms, and lowers the risk of recurrent myocardial infarction in adult patients.

GNH India supplies Metoprolol Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across diverse markets.

Manufacturer / TM Owner

Teva Pharma Belgium N.V./S.A

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprolol Retard, a selective β1‑adrenergic blocker, is used in cardiovascular conditions that require heart‑rate control and reduced cardiac workload.

  • Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
  • Chronic heart failure: improves ventricular function and reduces hospitalisation.
  • Post‑myocardial infarction: lowers the chance of recurrent events and improves survival.

How It Works

  • Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation of adenylate cyclase. This reduces intracellular cyclic AMP, leading to decreased heart rate, contractility, and cardiac output, while also lowering renin release from the kidneys, contributing to blood‑pressure reduction.

Side Effects

Metoprolol Retard may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

  • Fatigue: feeling of tiredness or lack of energy.
  • Dizziness: light‑headed sensation, especially on standing.
  • Bradycardia: slower than normal heart rate.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Severe bradycardia or heart block: may require medical attention.
  • Hypotension: marked drop in blood pressure.
  • Bronchospasm: tightening of airway muscles, especially in asthmatic patients.
  • Allergic reactions: rash, itching, swelling, or anaphylaxis.

Precautions & Warnings

Before prescribing Metoprolol Retard, clinicians should consider several safety aspects.

  • Dose adjustment in renal impairment: reduce dose as needed based on renal function.
  • Monitor heart rate: avoid use if resting heart rate is below 60 bpm.
  • Caution in asthma or COPD: β1‑selectivity may still affect bronchial tone.
  • Avoid abrupt discontinuation: taper to prevent rebound hypertension.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Metoprolol Retard can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Non‑selective β‑blockers: additive bradycardia.
  • Calcium channel blockers (verapamil, diltiazem): risk of severe AV block.
  • Clonidine: possible rebound hypertension if stopped.
  • Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance hypotensive effect.
  • ACE inhibitors or ARBs: additive blood‑pressure lowering.
  • SSRIs or other antidepressants: potential increase in bradycardia.

Frequently Asked Questions

Metoprolol Retard is prescribed for high blood pressure (hypertension), chest pain due to reduced blood flow (angina pectoris), chronic heart failure, and to reduce the risk of further heart attacks after a myocardial infarction. It works by lowering heart rate and cardiac output.

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart, decreasing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, reduced force of contraction, and lower blood pressure, helping to relieve strain on the cardiovascular system.

The appropriate dose of Metoprolol Retard is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Metoprolol Retard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol Retard is a β1‑selective blocker formulated as an extended‑release tablet, offering once‑daily dosing and smoother plasma concentrations compared with immediate‑release agents. Compared with non‑selective beta blockers, it has a lower risk of bronchospasm but shares similar cardiovascular effects.

Metoprolol Retard should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources.

Metoprolol Retard is taken orally as a whole extended‑release tablet, usually once daily with or without food. The tablet should not be split, chewed, or crushed, as this can alter the release profile and affect efficacy.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, severe dizziness, or breathing difficulties.

Metoprolol Retard is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, in those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and in patients experiencing cardiogenic shock.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Succinate (Ph. Eur.)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT